Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Serdexmethylphenidate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
    Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    28 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/28/2854508/16626/en/Zevra-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Updates.html

    GLOBENEWSWIRE
    28 Mar 2024
    Share Share
    Journal Frontiers in Psychiatry Publishes Analysis of With ADHD
    Journal Frontiers in Psychiatry Publishes Analysis of With ADHD

    26 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/journal-frontiers-in-psychiatry-publishes-analysis-of-open-label-safety-study-showing-improvements-in-sleep-habits-for-children-with-adhd-after-treatment-with-azstarys-serdexmethylphenidate-and-dexmethylphenidate-301862645.html

    PR NEWSWIRE
    26 Jun 2023
    Share Share
    Corium's Medication AZSTARYS Had No Significant Impact on Children's Weight
    Corium's Medication AZSTARYS Had No Significant Impact on Children's Weight

    22 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/coriums-novel-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-had-no-clinically-significant-impact-on-childrens-weight-and-height-growth-rate-301830739.html

    PR NEWSWIRE
    22 May 2023
    Share Share
    Corium's Novel ADHD Medication AZSTARYS Shown Safe and Effective in Study
    Corium's Novel ADHD Medication AZSTARYS Shown Safe and Effective in Study

    22 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/coriums-novel-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-shown-safe-and-effective-in-long-term-study-301752562.html

    PR NEWSWIRE
    22 Feb 2023
    Share Share
    KemPharm Receives FDA Orphan Designation for Serdexmethylphenidate for (IH)
    KemPharm Receives FDA Orphan Designation for Serdexmethylphenidate for (IH)

    18 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/18/2559035/16626/en/KemPharm-Receives-FDA-Orphan-Drug-Designation-for-Serdexmethylphenidate-SDX-for-the-Treatment-of-Idiopathic-Hypersomnia-IH.html

    GLOBENEWSWIRE
    18 Nov 2022
    Share Share
    Corium to Present Positive Data on AZSTARYS and ADLARITY at Psych Congress 2022
    Corium to Present Positive Data on AZSTARYS and ADLARITY at Psych Congress 2022

    13 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/corium-to-present-positive-data-on-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-and-alzheimers-disease-medication-adlarity-donepezil-transdermal-system-at-psych-congress-2022-301622663.html

    PRNEWSWIRE
    13 Sep 2022
    Share Share